Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance.
Madeddu G, De Socio GV, Ricci E, Quirino T, Orofino G, Carenzi L, Franzetti M, Parruti G, Martinelli C, Vichi F, Penco G, Dentone C, Celesia BM, Maggi P, Libertone R, Bagella P, Di Biagio A, Bonfanti P; C.I.S.A.I. Group, Italy. Madeddu G, et al. Among authors: parruti g. Int J Antimicrob Agents. 2015 Mar;45(3):289-94. doi: 10.1016/j.ijantimicag.2014.10.013. Epub 2014 Nov 13. Int J Antimicrob Agents. 2015. PMID: 25476452
An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir.
Bonfanti P, Martinelli C, Ricci E, Carradori S, Parruti G, Armignacco O, Magnani C, Quirino T; CISAI Group (Italian Coordinators for the Study of Allergies HIV Infection). Bonfanti P, et al. Among authors: parruti g. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):317-20. doi: 10.1097/01.qai.0000164248.56722.3c. J Acquir Immune Defic Syndr. 2005. PMID: 15980692
Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study.
Bonfanti P, Ricci E, de Socio G, Zeme D, Carradori S, Penco G, Parruti G, Grosso C, Madeddu G, Vichi F, Bini T, Martinelli C, Melzi S, Quirino T; CISAI Study Group. Bonfanti P, et al. Among authors: parruti g. J Acquir Immune Defic Syndr. 2006 May;42(1):128-31. doi: 10.1097/01.qai.0000219775.20174.2d. J Acquir Immune Defic Syndr. 2006. PMID: 16763502 No abstract available.
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project.
Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, Penco G, Rosella E, Miccolis S, Melzi S, Mura MS, Landonio S, Ricci E, Quirino T; CISAI Group. Madeddu G, et al. Biomed Pharmacother. 2008 Jan;62(1):6-11. doi: 10.1016/j.biopha.2007.04.008. Epub 2007 May 29. Biomed Pharmacother. 2008. PMID: 17574807
Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study.
De Socio GV, Parruti G, Quirino T, Ricci E, Schillaci G, Adriani B, Marconi P, Franzetti M, Martinelli C, Vichi F, Penco G, Sfara C, Madeddu G, Bonfanti P; CISAI study group. De Socio GV, et al. Among authors: parruti g. J Infect. 2008 Jul;57(1):33-40. doi: 10.1016/j.jinf.2008.03.007. Epub 2008 Apr 24. J Infect. 2008. PMID: 18436307
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting.
Zazzi M, Prosperi M, Vicenti I, Di Giambenedetto S, Callegaro A, Bruzzone B, Baldanti F, Gonnelli A, Boeri E, Paolini E, Rusconi S, Giacometti A, Maggiolo F, Menzo S, De Luca A; ARCA Collaborative Group. Zazzi M, et al. J Antimicrob Chemother. 2009 Sep;64(3):616-24. doi: 10.1093/jac/dkp252. Epub 2009 Jul 19. J Antimicrob Chemother. 2009. PMID: 19620134 Free article.
Chronological and biological age in HIV infection.
De Socio GV, Ricci E, Parruti G, Maggi P, Madeddu G, Quirino T, Bonfanti P. De Socio GV, et al. Among authors: parruti g. J Infect. 2010 Nov;61(5):428-30. doi: 10.1016/j.jinf.2010.09.001. Epub 2010 Sep 15. J Infect. 2010. PMID: 20833202 No abstract available.
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group. Prosperi MC, et al. J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927. J Med Virol. 2010. PMID: 20981785
268 results